Efficacy of cyclin-dependent kinase 4/6 inhibitors in patients with metastatic hormone positive breast cancer: a single institutional study from India

PURPOSE: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have shown marked benefit in the treatment of hormone positive metastatic breast cancer (HR+ MBC). There are limited real-world studies with palbociclib and ribociclib. Here we report our experience with CDK4/6 inhibitors in these groups of pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Ganguly, Sandip, Mukherjee, Navonil, Mandal, Sayan, Roy, Somnath, Agarwal, Sanjit, Biswas, Bivas, Ghosh, Joydeep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666281/
https://www.ncbi.nlm.nih.gov/pubmed/36405937
http://dx.doi.org/10.3332/ecancer.2022.1450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666281/
https://www.ncbi.nlm.nih.gov/pubmed/36405937
http://dx.doi.org/10.3332/ecancer.2022.1450

Ejemplares similares